Comparison between the effect of intracoronary bolus of tirofiban versus eptifibatide as adjunctive antiplatelet therapy on the outcome of primary coronary intervention in patients with acute anterior ST segment elevation myocardial infarction

Zaki, Tarek; Gamal, Adel; Hamady, Walid A. El; Mansour, Samar; Arab, Tamer M Abu

doi:10.1016/j.ehj.2011.09.002

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 176 patients with STEMI were available from three RCTs . Eptifibatide did not show significant differences compared to tirofiban in the risk of MACE and TIMI bleeding (MACE 1.89% vs15.09%, RR 0.25, 95% CI 0.06 to 1.12, P = 0.07; TIMI minor bleeding 8% vs 32.76%, RR 0.47, 95% CI 0.11 to 1.93, P = 0.22; TIMI major bleeding 0% vs 13.04%, RR 0.25, 95% CI 0.03 to 2.17, P = 0.49).…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta‐analysis

Zhou

Sun

et al. 2017

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

“…The results of the literature search were shown in Figure 1. Finally, we identified nine eligible studies with 1256 patients, of these, four articles [19][20][21][22] in Chinese, five articles [23][24][25][26][27]…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta‐analysis

Zhou

Sun

et al. 2017

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

Comparison of Intracoronary Tirofiban And Intravenous Tirofiban for Major Adverse Cardiac Events and Cerebrovascular Accident

Bukhari,

Rana,

Mirza

et al. 2023

PJHS

View full text Add to dashboard Cite

Major Adverse Cardiovascular Events (MACE) and and Cerebrovascular Accidents (CVA) have become primary areas of interest due to the ongoing focal research in cardiovascular diseases. Objective: To assess the frequency of major adverse cardiac events and cerebrovascular accidents for intracoronary tirofiban and intravenous tirofiban. Methods: It was a comparative study conducted at the Punjab Institute of Cardiology, Lahore from March 2019 to March 2020. A total of 250 patients of both genders, aged between 20 to 65 years were enrolled in this study who had STEMI and have high thrombus burden or TIMI flow grade < 3 during primary PCI. They were divided into two groups namely intracoronary tirofiban group and intravenous tirofiban. The impact of intracoronary tirofiban versus intravenous tirofiban outcomes were assessed. Results: Statistically insignificant difference in MACE (myocardial infarction, cerebrovascular accident & revascularization) between intracoronary & intravenous tirofiban groups was noted. The frequency distribution for cerebrovascular accidents (CVA) showed that haemorrhage was found similar in both groups. Ischemic stroke, in patients of the intracoronary tirofiban group compared with intravenous tirofiban group, was 1 (0.8%) vs 3 (2.4%) with p-value 0.348 respectively. Reversible ischemic neurological deficit (RIND) was found in 3 (2.4%) in the intracoronary and 4 (3.2%) in the intravenous group. Transient ischemic attack (TIA) found in the intracoronary was 8(6.4%) whereas in the intravenous group was 9 (7.2%). Conclusions: The results of our study make us conclude that tirofiban when given intracoronary or intravenous does not show any significant difference for major adverse cardiac events and cerebrovascular accidents.

show abstract

Comparison between the effect of intracoronary bolus of tirofiban versus eptifibatide as adjunctive antiplatelet therapy on the outcome of primary coronary intervention in patients with acute anterior ST segment elevation myocardial infarction

Cited by 2 publications

References 28 publications

Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta‐analysis

Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta‐analysis

Comparison of Intracoronary Tirofiban And Intravenous Tirofiban for Major Adverse Cardiac Events and Cerebrovascular Accident

Contact Info

Product

Resources

About